Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation

Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation

Source: 
Pharmaceutical Business Review
snippet: 

IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia disorders, including insomnia associated with alcohol cessation (IAAC).